http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Veracyte Announces Next-Generation Percepta Genomic Sequencing Classifier Now Available to Physicians for Improved Lung Cancer Diagnosis
-
Veracyte Named a San Francisco Bay Area “Top Workplace” For Sixth Consecutive Year
-
Veracyte (VCYT) Reports Publication of Data Detailing Clinical Utility of RNA Sequencing-Based Testing
-
Veracyte Announces New Article Published in Cancer Cytopathology Detailing Clinical Utility of Its RNA Sequencing-Based Testing for Thyroid Cancer Diagnosis and Treatment
-
Veracyte Announces New Publication of Data Demonstrating Real-World Performance of the Afirma GSC in Thyroid Cancer Diagnosis
-
Veracyte Announces New Data Showing Potential of Afirma Genomic Test to Guide Targeted Treatment for Medullary Thyroid Cancer Concurrent with Diagnosis
-
Veracyte Announces Participation in Two Upcoming Investor Conferences
-
Veracyte Announces New Data Demonstrating Afirma Xpression Atlas’s Potential to Inform Treatment Selection for Patients with Medullary Thyroid Cancer to Be Presented at 2019 ASCO Annual Meeting
-
Veracyte (VCYT) Unveils Next-Generation Percepta Genomic Sequencing Classifier for Improved Lung Cancer Diagnosis
-
Veracyte Unveils Next-Generation Percepta Genomic Sequencing Classifier for Improved Lung Cancer Diagnosis
-
Veracyte Names Sangeeta Bhorade, M.D., Medical Director of Pulmonology
-
Veracyte to Present at the UBS Global Healthcare Conference
-
Veracyte Announces First Quarter 2019 Financial Results
-
Veracyte (VCYT) Receives Regulatory Authorization to Offer Envisia Genomic Classifier for Patients in New York State
-
Veracyte Receives Regulatory Authorization to Offer Envisia Genomic Classifier for Patients in New York State
-
Veracyte Names Alfred Bowie, Jr., Ph.D. as Vice President, Corporate and Business Development
-
Veracyte (VCYT) Announces Publication Highlighting Afirma GSC’s Ability to Rule Out Cancer in Thyroid Nodule Subtype
-
Veracyte Announces Publication Highlighting Afirma GSC’s Ability to Rule Out Cancer in Challenging Thyroid Nodule Subtype
-
Veracyte to Release First Quarter 2019 Financial Results on April 30, 2019
-
Veracyte Announces Data Published in The Lancet Respiratory Medicine Demonstrate that the Envisia Genomic Classifier Improves Diagnosis of IPF
-
Veracyte Announces Participation in the 18th Annual Needham Healthcare Conference
-
Veracyte Announces New Afirma Xpression Atlas Data that Advance Genomic Understanding of Medullary Thyroid Cancer
-
Veracyte Announces Sponsorship of the Climb to Fight Cancer’s Team Kilimanjaro Expedition
-
Veracyte Announces New Afirma Xpression Atlas Data on Medullary Thyroid Cancer to Be Presented at ENDO 2019
-
Veracyte (VCYT) Receives Final Medicare Coverage Policy for Envisia Genomic Classifier
-
Veracyte Receives Final Medicare Coverage Policy for Envisia Genomic Classifier
-
Veracyte Announces Fourth Quarter and Full-Year 2018 Financial Results and Provides 2019 Financial Outlook
-
Veracyte Announces Participation in Upcoming Investor Conferences
-
Veracyte to Release Fourth Quarter and Full-Year 2018 Financial Results February 25, 2019
-
Veracyte to Present at the 21st Annual Needham Growth Conference
-
Veracyte (VCYT) Reports Strategic Collaboration with Johnson & Johnson (JNJ) Innovation in Battle Against Lung Cancer
-
Veracyte Announces Strategic Collaboration with Johnson & Johnson Innovation in Battle Against Lung Cancer
-
Veracyte to Present at the 37th Annual J.P. Morgan Healthcare Conference
-
Veracyte Announces Expansion of Envisia Genomic Classifier Early Access Program
-
Veracyte to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum
-
Veracyte Announces Publication of Data Demonstrating “Real World” Performance of Afirma GSC in Thyroid Cancer Diagnosis
-
Veracyte Announces Third Quarter 2018 Financial Results
-
Veracyte to Host Conference Call and Webcast to Discuss Third Quarter 2018 Financial Results on Monday, October 29, 2018
-
Veracyte Announces Presentation of “Real World” Clinical Utility Data at CHEST 2018 Showing Percepta Classifier Reduces Invasive Procedures in Lung Cancer Diagnosis
-
Veracyte Announces Presentation of Data Confirming Envisia Genomic Classifier’s Ability to Improve Diagnosis of Idiopathic Pulmonary Fibrosis
-
Veracyte (VCYT) Reports New Data from Six Studies Highlighting 'Real World' Performance of Afirma GSC and Xpression Atlas in Thyroid Cancer Diagnosis
-
Veracyte Announces that New Data from Multiple Studies Demonstrate “Real World” Performance of Afirma GSC and Xpression Atlas in Thyroid Cancer Diagnosis
-
Veracyte to Present at the Cantor Fitzgerald Global Healthcare Conference
-
Veracyte (VCYT) Announces New Data Reinforcing Clinical Value of Genomic Tests In Lung Disease Diagnoses to Be Presented at CHEST
-
Veracyte Announces New Data Reinforcing Clinical Value of Genomic Tests In Lung Disease Diagnoses to Be Presented at CHEST Annual Meeting 2018
-
Veracyte Announces Multiple Studies to Be Presented at ATA Annual Meeting Demonstrating “Real World” Performance of Afirma GSC and Xpression Atlas in Thyroid Cancer Diagnosis
-
Veracyte Achieves Major Medicare Milestone for the Envisia Genomic Classifier
-
Veracyte to Present at the Morgan Stanley 16th Annual Global Healthcare Conference
-
Veracyte Names Angeline McCabe as Vice President, Investor Relations and Corporate Communications
-
Veracyte to Present at the Canaccord Genuity 38th Annual Growth Conference

